Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0352W HIGH $13.19
Volume
7.83 M
Value Traded
10.14 M
Short % Float
19.33%
-16.6%Week
-29.84%1 Month
-42.97%3 Month
-58.85%6 Month
+72.36%5 Year
+72.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
338.81 M
EPS (TTM)
-0.77
P/E Ratio
-
Ent. Value
401.55 M
Total Shares
153.29 M
Float Shares
136.84 M
Insiders
10.74%
Institutions
47.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ASPI Catalyst Timeline
Dated clinical, regulatory and corporate events for ASP Isotopes Inc.
Past FDA Catalysts and PDUFA Decisions
How ASPI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every ASPI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ryan Robert John AndrewDirector | Buy | 15,000 675,222 held | $2.68 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASPI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ASPI for Q2 2026. | ||||
ASPI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ASPI ranks across every disease it competes in
Competitive Position is a premium feature
See how ASPI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialASPI News
ASPI▲ +24.9%on this news· ran to +40% by day 3
ASP Isotopes Implements Engineering Enhancements to Silicon-28 Enrichment Facility; Successfully Restarts First 18 Stages of Silicon-28 Enrichment Facility; Commercial Shipments of Enriched Silicon-28 Expected to Commence in Q3 2026
ASP Isotopes has previously announced that it has signed three commercial contracts for the supply of enriched Silicon-28 to U.S.-based customers, and expects to make initial commercial shipments of enriched Silicon-28 in Q3 2026. The first 18 stages (comprising segments one and
Read more →ASPI▲ +15.6%on this news
Quantum Leap Energy Enters into Memorandum of Understanding with European Nuclear Technology Company for Advanced Nuclear Fuel Supply Collaboration
ASPI Isotopes Inc. announced that its subsidiary, Quantum Leap Energy, has signed a non-binding Memorandum of Understanding with a European nuclear technology company. This partnership aims to assess the feasibility of a long-term collaboration for the supply of high assay low enriched uranium (HALEU). The MOU outlines potential uranium feedstock provisions and enrichment processes, with deliveries expected to begin in 2028.
Read more →ASPI▲ +8%on this news· ran to +21% by day 3shared move
Quantum Leap Energy Appoints Dr. Peter Fiske to Strategic Advisory Board
ASPI Isotopes Inc. announced the appointment of Dr. Peter Fiske to the Strategic Advisory Board of its subsidiary, Quantum Leap Energy. Dr. Fiske brings significant experience in technology commercialization and advanced materials, which will aid QLE in scaling its operations in the nuclear energy market. This appointment coincides with QLE's strategic initiatives to enhance its presence in clean energy solutions.
Read more →ASPI▲ +12.9%on this news
ASP Isotopes Inc. Provides Business Update
ASP Isotopes Inc. provided a business update highlighting operational advancements in nuclear medicine, electronics, and nuclear energy. The company anticipates its first commercial shipments of isotopes in 2026 and aims for an EBITDA exceeding $300 million by 2031. Despite a strong cash position, it reported a significant net loss for 2025.
Read more →ASPI▲ +6.4%on this news· ran to +28% by day 3shared move
ASP Isotopes to Host Business Update Conference Call on April 13, 2026, at 8:00 AM ET
DALLAS, April 10, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that
Read more →ASPIASP Isotopes Announces Strategic Collaboration Between Quantum Leap Energy and University of Bristol to Design Advanced Laser Research Facility
ASP Isotopes Inc. announced a collaboration between its subsidiary Quantum Leap Energy and the University of Bristol to design a lithium laser research facility. This partnership aims to advance nuclear fuel technology and meet increasing market demand. The project will involve a comprehensive feasibility study and design work, potentially leading to a groundbreaking research hub.
Read more →ASPI▲ +14.6%on this newsshared move
ASP Isotopes Completes Well Drilling Required for Phase 1 of Renergen Helium Project Four Months Ahead of Schedule
ASP Isotopes has successfully completed the drilling for Phase 1 of the Renergen Helium Project ahead of schedule. The results indicate that the gas flow rates are capable of meeting or exceeding previous estimates, which significantly reduces execution risks. The company is focused on enhancing helium production amid ongoing supply challenges in the global market, particularly due to geopolitical tensions affecting major helium producers.
Read more →ASPIASP Isotopes to Participate in Canaccord Genuity’s 2nd Annual CG Virtual Sustainability Summit
DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today announced that
Read more →ASPIQuantum Leap Energy Appoints Nate Salpeter, Ph.D., a Key Opinion Leader in Fluid Dynamics and Energy Technology, as its Chief Technology Officer
ASPI Isotopes Inc. has appointed Dr. Nate Salpeter as Chief Technology Officer of its subsidiary, Quantum Leap Energy. Dr. Salpeter, an expert in energy technology optimization, will focus on enhancing QLE's technologies and leading technical efforts. His extensive background in fluid dynamics and nuclear energy positions him to drive the company's commercial goals forward.
Read more →ASPIASP Isotopes Announces Quantum Leap Energy and Necsa Advance Strategic Collaboration Aimed at Production of HALEU Nuclear Fuel
ASP Isotopes Inc. announced a collaboration between its subsidiary Quantum Leap Energy and the South African Nuclear Energy Corporation to develop a facility for producing High Assay Low Enriched Uranium (HALEU). This partnership aims to enhance nuclear fuel supply for advanced reactors, leveraging both companies' technologies and infrastructure. The initiative is crucial for meeting the growing demand for HALEU in the nuclear energy sector.
Read more →ASPIASP Isotopes Announces Establishment of Quantum Leap Energy Strategic Advisory Board, Bolstering its Plans for the Nuclear Fuel Sector
DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of th
Read more →ASPIASP Isotopes Announces Quantum Leap Energy to Establish Global Headquarters in Austin, TX
DALLAS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced its plans for Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segme
Read more →ASPI▼ -8.8%on this news· ran to -21% by day 3
ASP Isotopes Inc. Provides Production Update on the Renergen Helium Project
ASP Isotopes Inc. provided a production update on the Renergen Helium Project, highlighting significant operational progress since April 2025. The project has seen improvements in drilling execution, gas production, and commercial readiness. Management anticipates achieving positive operational cash flow before the end of 2026, with ongoing upgrades to the processing plant and gas gathering infrastructure.
Read more →ASPIASP Isotopes Closes Acquisition of Renergen
ASP Isotopes has completed its acquisition of Renergen, creating a company focused on critical isotopes and helium production. The combined entity aims to leverage advanced technologies and significant funding to expand operations, particularly in high-demand sectors such as semiconductors and clean energy. This strategic move positions ASP Isotopes as a leading global provider in critical materials.
Read more →ASPIASP Isotopes Inc. Announces Receipt of Regulatory Approvals for Acquisition of Renergen Limited
ASP Isotopes Inc. has received all necessary regulatory approvals for its acquisition of Renergen Limited. The acquisition will allow Renergen shareholders to exchange their shares for ASP Isotopes shares. The merger is expected to create a leading entity in the isotope production market, with anticipated synergies beginning in 2026. A compliance certificate is awaited to finalize the scheme.
Read more →ASPIASP Isotopes Inc. Announces Paul Mann to Return from Temporary Leave of Absence as Executive Chairman and Chief Executive Officer
ASP Isotopes Inc. announced that Paul Mann will return as CEO effective January 19, 2026, after a temporary leave for health reasons. During his absence, Robert Ainscow served as Interim CEO. Mann expressed gratitude for the management team and highlighted the company's strengthened execution frameworks, indicating a positive outlook for 2026.
Read more →ASPI▲ +5.1%on this newsshared move
ASP Isotopes Announces Endowment of New Photonics Chair at Wits University to Advance Photonics Research
WASHINGTON, Nov. 28, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:) (“ASP Isotopes” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced the establishment of
Read more →ASPI▲ +5.4%on this news· ran to -18% by day 3
ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST
ASP Isotopes Inc. will hold a quarterly business update call on November 21, 2025, at 8:30 a.m. EST. The company focuses on developing technologies for isotope production across multiple industries, including healthcare and nuclear energy. Their proprietary Aerodynamic Separation Process aims to meet the increasing demand for isotopes used in quantum computing and green energy applications.
Read more →ASPI▼ -9.8%on this newsshared move
ASP Isotopes Announces Quantum Leap Energy’s Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
ASP Isotopes Inc. has announced that its subsidiary, Quantum Leap Energy LLC, has confidentially submitted a draft registration statement for a proposed initial public offering. The specifics regarding the number of shares and pricing are yet to be determined. This move is subject to SEC review and market conditions. ASP Isotopes focuses on producing isotopes for various industries, including healthcare and nuclear energy.
Read more →ASPI▲ +17.5%on this newsshared move
Quantum Leap Energy LLC Announces Private Placement of Convertible Notes Led by American Ventures LLC
Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc., has announced a private placement of convertible notes totaling $64.3 million. The offering is aimed at accredited investors and certain non-U.S. persons, with proceeds intended for developing laser enrichment production facilities. The notes may convert into common equity under specific conditions, enhancing QLE's financial flexibility.
Read more →About ASP Isotopes Inc.
Headquarters2200 ROSS AVENUE, SUITE 4575E, DALLAS, TX, 75201
Founded2021
BIOPHARMAWATCH ELITE PLUS
Trade the next ASPI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime